Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Non-Current Assets (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Non-Current Assets data on record, last reported at $62.9 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 54.15% year-over-year to $62.9 million; the TTM value through Sep 2025 reached $217.4 million, up 4.39%, while the annual FY2024 figure was $53.9 million, 6.63% up from the prior year.
  • Non-Current Assets reached $62.9 million in Q3 2025 per FBIO's latest filing, up from $49.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $106.6 million in Q3 2021 and bottomed at -$299.0 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $34.9 million, with a median of $53.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: tumbled 38.52% in 2022, then surged 117.76% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $50.0 million in 2021, then grew by 27.63% to $63.9 million in 2022, then decreased by 20.93% to $50.5 million in 2023, then rose by 6.63% to $53.9 million in 2024, then rose by 16.81% to $62.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $62.9 million in Q3 2025, $49.5 million in Q2 2025, and $51.2 million in Q1 2025.